Healthcare Industry News: Magnetic Resonance Imaging
News Release - June 8, 2006
MEDRAD MR Infusion System FDA Cleared for 3.0TThe First MR Compatible Infusion System Now Cleared for Latest 3.0T Magnet Strengths
INDIANOLA, Pa., June 8 (HSMN NewsFeed) -- MEDRAD received Food and Drug Administration (FDA) clearance for use of its Continuum MR Infusion System in magnetic resonance (MR) environments up to and including 3.0 Tesla (T). The new FDA clearance enables clinicians working in the latest 3.0T environments to infuse medications, sedatives, and other drugs while benefiting from Continuum's ease-of-use and dose enhancements.
"MEDRAD created the category for MR compatible infusion systems with the Continuum MR Infusion System," said Gary Bucciarelli, senior vice president, Magnetic Resonance Business Unit. "Innovation has been a hallmark of Continuum and the clearance for 3.0T helps us reach new patients with this advanced technology."
To learn more about Continuum use for 3.0T environments, customers and current Continuum users can contact their MEDRAD representative for information and to arrange to receive the upgrade kit.
Continuum was introduced in 2002 as the first MR compatible infusion system, meeting the need for safe and reliable infusion during MRI procedures in strengths up to 1.5T, the market standard at the time. With the advent of higher strength magnets, MEDRAD began extensive testing in 3.0T, and Continuum is now cleared to provide guidance for safety and performance in that environment. MR accessory equipment must meet safety standards and perform without interfering with the quality of medical images. Tests for attraction, homogeneity, artifact, and static magnetic field are designed to ensure that Continuum meets or exceeds these requirements, and the results confirm that it does.
In the most recent enhancement to Continuum, MEDRAD added a greater selection of drug-specific units of measurement, increasing the number of drugs that can be infused. It also helps prevent programming errors by reducing the confusion of manual conversions.
For over a decade, MEDRAD has delivered advanced technology to the MR suite and supported it with a robust global support organization. Other MEDRAD MR products include the Spectris Solaris® EP Injection System and a wide array of Leading Image(TM) Coils, as well as the Veris(TM) MR Patient Monitor, winner of the Frost & Sullivan Customer Value Enhancement Award in 2005.
MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2005 revenues were $411 million. MEDRAD, INC. is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD, INC. is a U.S. affiliate of Schering AG, Germany (NYSE: SHR ). For more information, visit MEDRAD's Website at www.medrad.com.
Cautionary Statement Regarding Forward-Looking Statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events, circumstances or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.